New treatments for genotype 1 chronic hepatitis C – focus on simeprevir

Chronic hepatitis C virus (HCV) infection causes end-stage liver diseases and hepato cellular carcinoma. In the USA, Canada, and Japan, simeprevir – one of the second-generation HCV NS3/4A protease inhibitors – in combination with peginterferon α-2a or 2b plus ribavirin has recently been approved fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanda, Tatsuo, Nakamoto, Shingo, Wu, Shuang, Yokosuka, Osamu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043814/
https://www.ncbi.nlm.nih.gov/pubmed/24920913
http://dx.doi.org/10.2147/TCRM.S50170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043814/
https://www.ncbi.nlm.nih.gov/pubmed/24920913
http://dx.doi.org/10.2147/TCRM.S50170

Ejemplares similares